Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is amongst the top gainers in the early hours with an unusual massive volume of 5.50 million shares and zoomed 19.29% at $2.35. The stock has a 52-week range of $0.81-$3.78. The company announced that it obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load. LX4211, dosed as a single agent, provided improvements in glycemic control, demonstrating statistically significant benefits in the primary and multiple secondary efficacy endpoints.
Subscribe to daily free stock newsletter by visiting: http://www.pennystockpickreport.com/
GenVec, Inc. (NASDAQ:GNVC) rallied 7.36% to $2.08 on a massive volume of 2.97 million shares. The stock today also touched a new 52 week high at $2.23. GenVec, Inc. (GenVec) is a clinical stage biopharmaceutical company developing gene-based therapeutic drugs and vaccines. Its lead product candidate, TNFerade biologic (TNFerade), is being developed for use in the treatment of cancer. Using GenVec’s core adenovector technology, TNFerade stimulates the production of tumor necrosis factor alpha (TNFa), a known anti-tumor protein, in cells of the tumor.
Hollis-Eden Pharmaceuticals Inc. (NASDAQ:
About http://www.pennystockpickreport.com/
Penny Stock Pick Report offers a stock newsletter on OTC, PINKSHEETS ,OTCBB, and AMEX Stocks. Our subscribers receive daily up to date stock information on midcap, smallcap penny stocks and also stocks that are traded at NASDAQ and NYSE stock exchange. If you wish to feature your organization on our website then you can contact us at the email given below.